drugset / Trial / NCT02621359
A Two Week Nitazoxanidebased Quadruple Regimen
NaSingle-groupOpen-labelTreatment
Summary
Helicobacter pylori (H. pylori) infection is a global health problem as it is associated with peptic ulcers, chronic gastritis, duodenitis, and stomach cancer. Therefore, the eradication of the pathogen is of critical importance to reduce H. pylori-related complications . However, due to increasing antibiotic resistance, eradication of Helicobacter pylori has become more challenging. With a great decline in the eradication rate of standard triple therapy for Helicobacter pylori to below 70% in many countries. Treatment with triple therapy, which is the most frequently recommended, fails to eradicate H. pylori in approximately 20% of cases .
Timeline
- Start
- 2015-01
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxycycline | Small molecule | 100 mg | — |
| Subject | Levofloxacin | Small molecule | 500 mg | — |
| Subject | Nitazoxanide | Other / unclassified | 500 mg | — |
| Subject | Omeprazole | Other / unclassified | 40 mg | — |